Trial
NCT00978432
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Anne Beaven, MD
Collaborators
Novartis
Condition
Diffuse Large B-cell Lymphoma
Intervention
RAD001
Why stopped
The toxicity seemed to outweigh the benefit.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-11-25